secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2023-09-18T23:59:59+00:00
Accession:  0001104659-23-101377
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics appoints Mark Velleca as CEO; David Epstein steps down
--------------------------------------------------------------------------------

- David M. Epstein separated as President and CEO effective Sept 15, 2023; remains on board until 2024 annual meeting.
- Mark Velleca, M.D., Ph.D. appointed President and CEO effective Sept 16, 2023; continues as Chairman.
- Velleca receives $620K base salary, 55% target bonus, and stock options for 1,000,000 shares.
- Samarth Kulkarni appointed Lead Independent Director; Audit/Nominating committees unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465923101377/0001104659-23-101377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465923101377/tm2326304d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-101377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer